Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ravaud

Showing results (181-190 of 221) with videos related to

Pageof 23
Sort By:
Journal for Immunotherapy of Cancer|October 10, 2020
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysisAndrea B Apolo, John A Ellerton, Jeffrey R Infante, et al.
Annals of the Rheumatic Diseases|November 18, 2017
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Léa Rouxel, Thomas Barnetche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Functional decline in older patients with cancer receiving first-line chemotherapyStéphanie Hoppe, Muriel Rainfray, Marianne Fonck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2018
Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT TrialLaetitia Mauge, Arnaud Mejean, Laure Fournier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.
Molecular Cancer|October 21, 2021
Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progressionLindsay S Cooley, Justine Rudewicz, Wilfried Souleyreau, et al.
European Urology Oncology|February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS TrialBernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
European Urology|April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
European Urology|October 3, 2017
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival ResultsRobert J Motzer, Alain Ravaud, Jean-Jacques Patard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2Stéphane Oudard, Stéphane Culine, Yann Vano, et al.
Pageof 23

Showing results (181-190 of 221) with videos related to

Sort By:
Pageof 23
Journal for Immunotherapy of Cancer|October 10, 2020
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysisAndrea B Apolo, John A Ellerton, Jeffrey R Infante, et al.
Annals of the Rheumatic Diseases|November 18, 2017
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Léa Rouxel, Thomas Barnetche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Functional decline in older patients with cancer receiving first-line chemotherapyStéphanie Hoppe, Muriel Rainfray, Marianne Fonck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2018
Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT TrialLaetitia Mauge, Arnaud Mejean, Laure Fournier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.
Molecular Cancer|October 21, 2021
Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progressionLindsay S Cooley, Justine Rudewicz, Wilfried Souleyreau, et al.
European Urology Oncology|February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS TrialBernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
European Urology|April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
European Urology|October 3, 2017
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival ResultsRobert J Motzer, Alain Ravaud, Jean-Jacques Patard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2Stéphane Oudard, Stéphane Culine, Yann Vano, et al.
Pageof 23